Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A randomized, double blind, parallel group, placebo controlled, multi center dose ranging study of solifenacin succinate in combination with tamsulosin hydrochloride compared with solifenacin succinate monotherapy and tamsulosin hydrochloride monotherapy in males with lower urinary tract symptoms (LUTS) associated with benign prostatic hyperplasia (BPH)

Next Previous
Trial Profile

A randomized, double blind, parallel group, placebo controlled, multi center dose ranging study of solifenacin succinate in combination with tamsulosin hydrochloride compared with solifenacin succinate monotherapy and tamsulosin hydrochloride monotherapy in males with lower urinary tract symptoms (LUTS) associated with benign prostatic hyperplasia (BPH)

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 04 Apr 2022

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Solifenacin (Primary) ; Tamsulosin (Primary)
  • Indications Benign prostatic hyperplasia; Lower urinary tract symptoms
  • Focus Therapeutic Use
  • Acronyms SATURN
  • Sponsors Astellas Pharma

    • Most Recent Events

    • 01 Aug 2012 New source identified and integrated (German Clinical Trials Register DRKS00004046).
    • 21 Jun 2012 Additional locations added as reported by European Clinical Trials Database record.
    • 10 Dec 2008 Actual patient number (919) added as reported by ClinicalTrials.gov.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top